Clinical Trials | November 10, 2025
Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Relmada expects to initiate its Phase 3 program in the first half of 2026
Relmada expects to initiate its Phase 3 program in the first half of 2026
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Dabur India has reported total income of Rs. 3,331.45 crore during the period ended September 30, 2025
Tatva Chintan Pharma Chem has reported total income of Rs. 124.52 crore during the period ended September 30, 2025
Subscribe To Our Newsletter & Stay Updated
